Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $79M (down 31.8% year over year) with net income of −$28M.
Q3 2026 key financials · XBRL
- Revenue
- $79M
- −31.8% YoY · +23.6% QoQ
- Net income
- −$28M
- −124.3% YoY · −158.7% QoQ
- Operating margin
- -19.4%
- EPS (diluted)
- −$1.32
- −122.4% YoY · −157.4% QoQ
Source: XBRL data from the LIGAND PHARMACEUTICALS INC (LGND) Q3 2026 10-Q on SEC EDGAR. USD.
LIGAND PHARMACEUTICALS INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue and income $78.7M, down $36.7M or 32% YoY from $115.5M
- Net loss $28.5M vs net income $117.3M; operating costs 120% of revenue vs 52% YoY
- Best performer royalties $70.3M, up 51%; Filspari royalty revenue $16.8M vs $9.1M
- Cash, equivalents and short-term investments $447.4M vs $733.5M at December 31, 2025; operating cash flow $45.1M YTD
- XOMA acquisition and investments drove liquidity decline; management expects resources sufficient for at least twelve months
Risk Factors
- New acquisition risk triggered by July 14, 2026 XOMA Acquisition: integration may disrupt systems, personnel retention and royalty portfolio administration
- Royalty revenue risk: counterparties may buy out obligations below future royalties’ net present value
- Debt liquidity risk: 2030 Notes and 2031 Notes may require cash repurchases after specified events
- Financing risk: insufficient operating cash flow could force asset sales, debt restructuring or highly dilutive financing
- Litigation risk: potential XOMA Acquisition litigation disclosed, though not currently expected to be material
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LIGAND PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.